A program NVS has been oddly quiet about (nothing in today’s PR or CC) is Elinogrel, the antiplatelet drug licensed from Portola. I haven’t heard anything about it since the brief mention at 2010 AHA in #msg-56742275.
Has anybody here heard anything more recently?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.